All lobbying filings

DLA Piper LLP (US)

DLA Piper LLP (US) filed a Q4 report for Biohaven Pharmaceuticals, Inc. on January 16, 2026, reporting $60,000 in lobbying income.

Lobbying for Biohaven Pharmaceuticals, Inc. · A biopharmaceutical company.

As filed: DLA PIPER LLP (US) for BIOHAVEN PHARMACEUTICALS, INC.

All filings by DLA Piper LLP (US) · Everything Biohaven Pharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 16, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

Connecticut

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.